Turn Therapeutics Inc.
corporate_fare Company Profile
Turn Therapeutics Inc. (NASDAQ:TTRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for TTRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for TTRX spans 424B3, 8-K, S-3, 10-Q.
Recent high-impact activity:
- Turn Therapeutics Registers 25.4M Shares for Resale Under $85M GEM Equity Line
- Turn Therapeutics Posts New GX-03 Subgroup Data: 61.5% vs 8.3% vIGA Success at Week 4
- Turn Therapeutics Files $150M Shelf and Launches $50M TD Cowen ATM
- Turn Therapeutics Registers 25.4M Shares for Resale, ~83% of Outstanding, in S-3
- Turn Therapeutics 10-Q: $13.1M Nine-Month Loss, Going Concern, $10.4M Cash Into Q3 2027
Financial Snapshot
Short Interest & Short Volume
5.87 days to coverFINRA reported short interest of 530,526 shares in TTRX as of the October 30, 2026 settlement, a 23.0% increase from the prior period — about 5.9 days to cover at its recent average daily volume. On November 20, 2026, 55.1% of TTRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for TTRX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.
ATM Prospectus Filed, No Sales Yet · Dilution Math Quantified
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →